In cellular and murine models, investigation into the inhibition of FTO by a derivative of meclofenamic acid (which is an inhibitor that associates with a nucleic acid substrate binding site) suggests that FTO suppression by selective inhibitors may be a successful strategy for the treatment of acute myeloid leukemia [96,236]. The gene discussed is FTO; the disease is acute myeloid leukemia.